1. C-reactive protein as a possible modifier of Lipoprotein(a)-related risk for coronary heart disease in Europe: results from the BiomarCARE project. (3rd October 2022) Authors: Arnold, N; Blaum, C; Gossling, A; Zeller, T; Linneberg, A; Soderberg, S; Iacoviello, L; Sans, S; Leoni, V; Kee, F; Salomaa, V; Kuulasmaa, K; Blankenberg, S; Koenig, W; Waldeyer, C Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiovascular Disease. (11th November 2018) Authors: Summapund, J; Grant, E; Dickson, V; Matlock, D; Chaudhry, S; Katz, S; Blaum, C; Dodson, J Journal: Innovation in aging Issue: Volume 2(2018)Supplement 1 Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Risk scores for risk stratification in chronic coronary syndrome and their improvement by Gensini and SYNTAX scores. (14th October 2021) Authors: Blaum, C; Bay, B; Kroeger, F; Gossling, A; Lorenz, T; Max, L; Zeller, T; Schnabel, R; Clemmensen, P; Westermann, D; Kirchhof, P; Blankenberg, S; Seiffert, M; Brunner, F J; Waldeyer, C Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort. (14th October 2021) Authors: Blaum, C; Brunner, F J; Kroeger, F; Bay, B; Gossling, A; Lorenz, T; Graef, A; Zeller, T; Schnabel, R; Clemmensen, P; Westermann, D; Blankenberg, S; Seiffert, M; Waldeyer, C Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort. (25th November 2020) Authors: Blaum, C; Brunner, F.J; Kroeger, F; Braetz, J; Bay, B; Graef, A; Gossling, A; Lorenz, T; Zeller, T; Karakas, M; Schnabel, R.B; Westermann, D; Blankenberg, S; Seiffert, M; Waldeyer, C Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗